Back to search

Sweden· SE-20230801000099

Dalbavancin Zentiva 500 mg Pulver till koncentrat till infusionsvätska, lösning

A dalbavancin product containing dalbavancin, registered in Sweden by Zentiva k.s.. The same ATC class is registered in 16 of our 19 countries.

ATC J01XA04

Checked against Swedish Medical Products Agency (Sweden) on

Informational only — not a medical device.

SOURCE REGISTER · SESwedish Medical Products Agency (Sweden)normalisedDalbavancin Zentiva 500 mg Pulver til…ATCJ01XA04REGISTER NO.SE-20230801000099PACKS LISTED1CHECKEDOctober 1, 2026

Where it is registered

Dalbavancin is registered in 16 of 19 countries.

Countries holding a registration under ATC J01XA04 (dalbavancin), each read from that country’s own register.

  • This record: Sweden, from Swedish Medical Products Agency (Sweden)
  • 9 of them publish a price we can compare per daily dose

Dalbavancin · ATC J01XA04

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swedish Medical Products Agency (Sweden)
Active substance
Dalbavancin
Manufacturer
Zentiva k.s.
Country
Sweden (SE)
ATC code
J01XA04
ATC class
Dalbavancin
Defined daily dose
1.5 g, P
Reimbursed
Not published by this register
Source register
Swedish Medical Products Agency (Sweden)
Last checked
October 1, 2026

Packs & prices · 1

  • se_varunummer
    20230801000099

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for dalbavancin.

Graded by severity as the source publishes them — 7 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Dalbavancin · interactions on record

7 records

  • 7 moderate

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • Levonorgestrel and ethinylestradiolG03AA07moderate
  • Desogestrel and ethinylestradiolG03AA09moderate
  • Drospirenone and ethinylestradiolG03AA12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dalbavancin in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dalbavancin products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

  • Austria · Dalbavancin, Dalbavancin Accord
  • Germany · Dalbavancin Accord, Dalbavancin Baxter
  • Denmark · Dalbavancin Adalvo, Dalbavancin Teva
  • Spain · Dalbavancin Dr. Reddys, Dalbavancina Accord
  • Finland · Dalbavancin Adalvo, Dalbavancin Tillomed
  • France · Dalbavancine Accord, Dalbavancine Reddy Pharma
  • United Kingdom (Northern Ireland) · Dalbavancin Accord, Dalbavancin Reig Jofre Uk
  • Greece · Bavalda, Dalbavancin Accord
  • Iceland · Xydalba
  • Italy · Dalbavancina Accord, Dalbavancina Dr. Reddy’s
  • Liechtenstein · Xydalba
  • Malta · Bavalda, Dalbavancin Adalvo
  • Norway · Dalbavancin Tillomed, Xydalba
  • Poland · Dalbavancin Accord, Dalbavancin Reig Jofre
  • Portugal · Dalbavancina Anfarm
  • Slovakia · Dalbavancin Adalvo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ce03e1ab-13d3-4bbe-8a63-6f00c4a81f08
GET /v1/drugs/ce03e1ab-13d3-4bbe-8a63-6f00c4a81f08?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "lakemedelsverket",
  "doc_types": [
    "PL",
    "SmPC"
  ],
  "se_npl_id": "20230801000099",
  "product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20230801000099",
  "product_doc_link": "https://docetp.mpa.se/LMF/Dalbavancin%20Zentiva%20500%20mg%20powder%20for%20concentrate%20for%20solution%20for%20infusion%20SmPC_09001bee84b69db9.pdf"
}

See everything about dalbavancin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.